e-learning
resources
Copenhagen 2005
Monday 19.09.2005
Muscle training and chronic lung disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effects of EXercise TRAining in Sarcoidosis
M. A. Spruit, M. J. Thomeer, R. Gosselink, E. Derom, M. G. Demedts, M. Decramer (Leuven, Ghent, Belgium)
Source:
Annual Congress 2005 - Muscle training and chronic lung disease
Session:
Muscle training and chronic lung disease
Session type:
Oral Presentation
Number:
2781
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. A. Spruit, M. J. Thomeer, R. Gosselink, E. Derom, M. G. Demedts, M. Decramer (Leuven, Ghent, Belgium). Effects of EXercise TRAining in Sarcoidosis. Eur Respir J 2005; 26: Suppl. 49, 2781
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Pulmonary sarcoidosis
Related content which might interest you:
Effect of Antifibrotic Therapies in Patients with Interstitial Pneumonia with Autoimmune Features
Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment
Year: 2020
Idiopathic Pulmonary Haemosiderosis; Factors That Effect Prognosis
Source: Virtual Congress 2020 – Tip the hat to paediatric bronchology
Year: 2020
Effects of Infliximab on FDG Uptake and Small Fiber Neuropathy Symptoms in Sarcoidosis Patients
Source: Virtual Congress 2021 – Better understanding of sarcoidosis: new keys
Year: 2021
Prevalence and Characteristics of Patients Receiving Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Development Of A Machine Learning Combination With Deep Learning For Diagnosing Idiopathic Pulmonary Fibrosis In Chronic Interstitial Lung Disease
Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020
Differential Expression of Plasma Metabolites in Patients with Pulmonary Sarcoidosis is Associated with Clinical Behavior
Source: International Congress 2018 – Sarcoidosis: from basic research to patient outcomes
Year: 2018
Genetic Profiles of Clinical Features in Sarcoidosis
Source: International Congress 2018 – Granulomatous disorders: epidemiology, genotype and phenotype
Year: 2018
A new Humanized Mouse Model for Idiopathic Pulmonary Fibrosis and Effects of Nintedanib Treatment
Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias
Year: 2018
Modes of Disease Progression in Different Forms of Interstitial Lung Disease with Usual Interstitial Pneumonia Histology in Patients with Idiopathic and Non-idiopathic Etiologies - A Single Center Experience
Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside
Year: 2019
Diagnosis and Treatment of Chronic Pulmonary Embolism
Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease
Year: 2014
Diagnosis and Treatment of Chronic Pulmonary Embolism
Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease
Year: 2018
Immunogenicity of Mepolizumab in Patients with Severe Eosinophilic Asthma: Experience from the Clinical Development Program
Source: International Congress 2018 – Novel immunology-based therapies in asthma and COPD
Year: 2018
Clinical Features and Prognosis of Acute exacerbation of Connective Tissue Diseases Associated Pulmonary Fibrosis------ Comparision with Idiopathic Pulmonary Fibrosis
Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Year: 2017
Effects of Thoracic Mobilization Techniques on Pulmonary Functions, Dyspnea and Health Status in Patients with Asthma
Source: International Congress 2019 – Role of the physiotherapist for patients with lung disease
Year: 2019
Effects of Ground-Based Walking Training in Pulmonary Hypertension
Source: Virtual Congress 2020 – Muscle, exercise capacity and symptoms of chronic lung disease: a physio update
Year: 2020
The Value of Voluntary Cough Sounds for Diagnosis of Pulmonary Disease
Source: International Congress 2018 – Clinical determinants of asthma and biomarkers
Year: 2018
O'Donnell Criteria as a Score of Bad Prognosis in Hospitalized Patients with Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis, an Observetional Study
Source: Virtual Congress 2021 – Bronchiectasis
Year: 2021
Unusual Presentation of a Systemic Disease: A Case Report
Source: International Congress 2019 – Epidemiology and management of acute pulmonary embolism
Year: 2019
Effects of Telerehabilitation on Peripheral Muscle Function in Pediatric Cystic Fibrosis Patients During Covid-19 Pandemic
Source: Virtual Congress 2021 – Physical activity, exercise training and (tele)rehabilitation in respiratory patients
Year: 2021
Assessment of Treatment Response in Granulomatous Lymphocytic Interstitial Lung Disease (GLILD)
Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept